This presentation provides translational proof-of-concept for agenT-797 in infectious/immune collapse contexts beyond oncology but lacks quantitative efficacy data. Watch for enrollment updates or early readout from the ongoing Phase 2 in severe acute lung injury. Catalytic value remains tied to Phase 2 data generation, not this single-case report.
Price Chart
Executive Summary
MiNK Therapeutics presented a single-case report at ATS 2026 showing that sequential immunotherapy with Anktiva (N-803) and its iNKT cell therapy agenT-797 suppressed fungal/bacterial pathogens, activated immune cell recruitment, reduced inflammatory signaling, and triggered tissue repair pathways in a critically ill patient with disseminated valley fever, ARDS, and hospital-acquired pneumonia after standard-of-care failed. The data support an ongoing Phase 2 trial in severe acute lung injury, but limited to a single case without quantitative efficacy or survival endpoints.
Key Facts
- Case report: sequential Anktiva (N-803) + agenT-797 in critically ill patient with disseminated Coccidioides immitis, ARDS, and Pseudomonas pneumonia
- Observed: pathogen suppression, immune cell recruitment into lung, reduced early inflammatory signaling, activation of tissue repair pathways
- AgenT-797 already has prior safety data in moderate-severe ARDS (favorable safety, improved survival, decreased secondary infections per prior disclosure)
- MiNK recently initiated a randomized Phase 2 trial of agenT-797 in severe acute lung injury / critical illness
- Clinical data is a single case (N=1) — no quantitative efficacy or survival endpoint was achieved (patient died from pre-existing mitral valve disease with cardiogenic shock)
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage biotech with $52M market cap
Risk Factors
- Patient died from pre-existing cardiac disease — confounds interpretation of immune response data
- Single case without comparator — limited statistical reliability
- Pre-revenue company with high cash burn; financing risk remains elevated
- Historical negative drift at T+20 for this ticker on prior bullish calls (net alpha -4.24% vs SPY)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298712 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 13, 2026 7w ago | Press Release | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 6, 2026 8w ago | Press Release | $11.00 $11.23 | ▲ +2.09% | ▲ +1.49% | $12.44 (+13.09%) |
May 28, 2026 18w ago | Press Release | $12.20 $11.64 | ▼ −4.59% | ▼ −1.45% | $12.44 (+1.97%) |
May 20, 2026 19w ago | Press Release | $10.72 $12.14 | ▲ +13.25% | ▲ +12.51% | $12.44 (+16.04%) |
May 15, 2026 20w ago | 8-K | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 15, 2026 20w ago | Press Release | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 14, 2026 20w ago | Press Release | $10.51 $12.02 | ▲ +14.37% | ▲ +15.23% | $12.44 (+18.36%) |
May 12, 2026 20w ago | Press Release | $11.41 $12.19 | ▲ +6.84% | ▲ +8.56% | $12.44 (+9.03%) |
May 8, 2026 20w ago | Press Release | $10.95 $11.82 | ▲ +7.95% | ▲ +8.25% | $12.44 (+13.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access